Abp β Inhibitors
Chemical inhibitors of Abp β can disrupt its activity through various molecular mechanisms, each targeting different aspects of its signaling pathways and functional interactions. Staurosporine acts as a broad-spectrum kinase inhibitor, directly targeting the ATP binding sites of kinases to prevent the phosphorylation necessary for Abp β activation. Similarly, Bisindolylmaleimide I targets protein kinase C (PKC), which is upstream of Abp β, leading to reduced phosphorylation and subsequent activation of Abp β. In another approach, Y-27632 inhibits the Rho-associated protein kinase (ROCK), which is crucial for actin cytoskeleton rearrangement, a process in which Abp β is also involved. By disrupting ROCK activity, Y-27632 indirectly affects Abp β's ability to modulate the cytoskeleton.
Further down the line of intracellular signaling, ML-7 and Blebbistatin target myosin II, albeit at different points in its activation cycle. ML-7 inhibits myosin light chain kinase (MLCK), which phosphorylates myosin II, a process that can be regulated by Abp β. Blebbistatin, on the other hand, inhibits the ATPase activity of myosin II, which is essential for muscle contraction and cell motility, functions that involve Abp β's regulatory roles. Gö 6976 disrupts the function of Abp β by inhibiting Ca2+/calmodulin-dependent protein kinase II (CaMKII), an upstream regulator of Abp β. PD 169316 and SB 203580 both target p38 MAP kinase, a significant player in the phosphorylation cascade that leads to Abp β activation, thereby reducing its activity. SP600125 inhibits c-Jun N-terminal kinase (JNK), which phosphorylates various substrates that affect the activity of Abp β. Lastly, LY294002 and Wortmannin inhibit PI3K, leading to decreased production of PIP3 and, consequently, reduced AKT signaling, which is necessary for the full activation of Abp β.
SEE ALSO...
Items 1 to 10 of 12 total
Display:
| Product Name | CAS # | Catalog # | QUANTITY | Price | Citations | RATING |
|---|---|---|---|---|---|---|
Staurosporine | 62996-74-1 | sc-3510 sc-3510A sc-3510B | 100 µg 1 mg 5 mg | $82.00 $150.00 $388.00 | 113 | |
Staurosporine inhibits Abp β by blocking ATP binding sites on kinases that are required for Abp β phosphorylation, a necessary step for its activation. | ||||||
Bisindolylmaleimide I (GF 109203X) | 133052-90-1 | sc-24003A sc-24003 | 1 mg 5 mg | $103.00 $237.00 | 36 | |
This chemical inhibits protein kinase C (PKC), which is upstream of Abp β signaling; inhibition of PKC leads to reduced Abp β phosphorylation and activation. | ||||||
Y-27632, free base | 146986-50-7 | sc-3536 sc-3536A | 5 mg 50 mg | $182.00 $693.00 | 88 | |
Y-27632 inhibits Rho-associated protein kinase (ROCK), which is involved in actin cytoskeleton organization that Abp β is associated with; inhibiting ROCK disrupts actin dynamics, which in turn can inhibit Abp β's ability to bind to actin and regulate cytoskeletal rearrangements. | ||||||
ML-7 hydrochloride | 110448-33-4 | sc-200557 sc-200557A | 10 mg 50 mg | $89.00 $262.00 | 13 | |
ML-7 inhibits myosin light chain kinase (MLCK), which is involved in the phosphorylation of myosin II, a process that Abp β can regulate; inhibition of MLCK leads to a reduction in myosin II activity and consequently inhibits Abp β's role in cytoskeletal organization. | ||||||
(S)-(−)-Blebbistatin | 856925-71-8 | sc-204253 sc-204253A sc-204253B sc-204253C | 1 mg 5 mg 10 mg 25 mg | $71.00 $260.00 $485.00 $949.00 | ||
Blebbistatin selectively inhibits myosin II ATPase activity, which is necessary for muscle contraction and cell motility that Abp β is involved in; by inhibiting this ATPase activity, Blebbistatin can inhibit Abp β's role in cell motility. | ||||||
Gö 6976 | 136194-77-9 | sc-221684 | 500 µg | $223.00 | 8 | |
Gö 6976 is a selective inhibitor of Ca2+/calmodulin-dependent protein kinase II (CaMKII), which is upstream of Abp β; inhibition of CaMKII can lead to a decrease in Abp β activity as Abp β is downstream of this kinase. | ||||||
SB 203580 | 152121-47-6 | sc-3533 sc-3533A | 1 mg 5 mg | $88.00 $342.00 | 284 | |
PD 169316 is a p38 MAP kinase inhibitor; by inhibiting p38 MAP kinase, it can reduce the phosphorylation and activation of downstream targets that are involved in the signaling cascade that Abp β is a part of, thus inhibiting Abp β activity. | ||||||
SB 202190 | 152121-30-7 | sc-202334 sc-202334A sc-202334B | 1 mg 5 mg 25 mg | $30.00 $125.00 $445.00 | 45 | |
SB 203580 specifically inhibits p38 MAP kinase, which is involved in the regulation of Abp β; by inhibiting p38 MAPK, SB 203580 can reduce the phosphorylation and subsequent activation of Abp β. | ||||||
SP600125 | 129-56-6 | sc-200635 sc-200635A | 10 mg 50 mg | $40.00 $150.00 | 257 | |
SP600125 inhibits c-Jun N-terminal kinase (JNK), which can phosphorylate substrates that affect Abp β activity; by inhibiting JNK, SP600125 can inhibit the activation of Abp β that depends on JNK signaling. | ||||||
LY 294002 | 154447-36-6 | sc-201426 sc-201426A | 5 mg 25 mg | $121.00 $392.00 | 148 | |
LY294002 is a PI3K inhibitor, and by inhibiting PI3K, it can lead to a reduction in PIP3 levels, which affects downstream AKT signaling that can regulate Abp β activity; by inhibiting this pathway, LY294002 can indirectly inhibit Abp β activity. | ||||||